Диссертация (1141376), страница 17
Текст из файла (страница 17)
Therapeutic Immunology/R.S. Geha, F.S. Rosen//II RSG Chapter. –1994. – V. 11. – P. 1-31.11493. Gnesh, G.M. Effect of Ca++ and Mg++ on anticomplementary sera in complementfixation tests/G.M. Gnesh//Proceedings of The Society for Experimental Biology andMedicine. – 1957. – V. 95.
– N 4. – P. 713-715.94. Goslings, W.R. A small molecular weight factor in aqueous humor acts on C1q toprevent antibody-dependent complement activation/W.R. Goslings, A.P. Prodeus,J.W. Streilein, et al.//Invest. Ophthalmol. Vis Sci. – 1998. – V. 39. – N 6. – P. 989995.95.
Gronski, P. Quality criteria for i.v. immunoglobulin’s: importance of tests andproduct properties/P. Gronski, E.J. Kanzy, H.J. Ronneberger, et al.//Developments inbiological standardization. – 1987. – N 67. – P. 239-256.96. Grumach, A.S. Complement and IgG subclasses in agammaglobulinemicpatients/A.S. Grumach, M. Kirschfink//Exp. Clin. Immunogenet. – 1995. – V. 12. –N 1.
– P. 10-15.97. Hofstaetter, T. S‐Sulfonation: a Reversible Chemical Modification of HumanImmunoglobulins Permitting Intravenous Application/T. Hofstaetter, P. Gronski,E.J. Kanzy, et al.//Vox Sang. – 1983. – V. 45. – N 2. – P. 155-165.98. Horgan, C. Complement-component-C3-opsonised immunoglobulin G anti-DNAantibodies do not bing effectively to red blood cell unless aggregated on a high-MrDNA matrix/C. Horgan, R.P.
Taylor//Biochem. –1984. – V. 224. – N 3. – P. 755-759.99. Ishizaka, K. Biologic Activity of Aggregated γ-Globulin II. A Study of VariousMethods for Aggregation and Species Differences/K. Ishizaka, T. Ishizaka//TheJournal of Immunology. – 1960. – V. 85. – N 2. – P. 163-171.100. Indian Pharmacopoeia. Human Normal Immunoglobulin for Intravenous Use.Volume III.
2010. – P. 2579-2586.101. Johnson, K.W. In vivo and in vitro effects of sodium azide mouse complement/K.W. Johnson, A.C. Anderson, A.E. Munson, et al.//Toxicol. Appl. Pharmacol. –1984. – V. 73. – N 3. – P. 559-563.102. Jolles, S. Clinical uses of intravenous immunoglobulin/S.
Jolles, W.A. Sewell,S.A. Misbah//Clin. Exp. Immunol. – 2005. – V. 142. – N 1. – P. 1-11.115103. Khadim, M.I. Non-specific fixation of complement: the anticomplementaryactivity/M.I. Khadim, N.A. Jafarey, S.J. Zuberi//Journal of the Pakistan MedicalAssociation. – 1978. – V. 28.
– N 5. – P. 59-61.104. Kotitschke,R.Qualitycontrolofimmunoglobulin’sforintravenousadministration/R. Kotitschke, G. Harbauer//Contributions to infusion therapy. – 1991.– N 28. – P. 124-31.105. Liumbruno, G. Recommendations for the transfusion of albumin andimmunoglobulin’s/G. Liumbruno, F. Bennardello, A. Lattanzio et al.//Blood Transfus.– 2009. – V.
7. – N 3. – P. 216-234106. Marcus, D.M. A study of the mechanism of the anticomplementary activity ofgamma-globulin/D.M. Marcus//The Journal of Immunology. – 1960. – N 84. – P.273284.107. Mayer, M.M. The activating effect of magnesium and other cations on thehemolytic function of complement/M.M. Mayer, A.G. Osler, O.G.
Bier, etal.//Journal of Experimental Medicine. – 1946. – V. 84. – N 6. – P. 535-548.108. Mayer, M.M. Complement and complement fixation. – Thomas CC (ed):Experimental Immunochemistry, Illinois, Springfield. 1961.109. Medgyesi, G.A. Safety aspects of intravenous immunoglobulin’s/G.A. Medgyesi,J. Kovács, G Füst, et al.//Immunological investigations. – 1988. – V. 17. – N 2. –P. 121-133.110. Miekka, S.I. Anticomplementary activity of human Immunoglobulin G:I.
Mechanism of the artifactual increase in anticomplementary activity of IgG duringassay/S.I. Miekka, I. Gozze//Vox Sang. – 1975. – V. 29. – P. 101–123.111. Montanari, V. Early decrease in total hemolytic complement activity (CH100)after fasting or intestinal bypass in the rat/V. Montanari, et al.//Eur. Surg. Res. –1986.
– V. 18. – N 1. – P. 36-40.112. Moreno-Indias, I. The complement system of the goat: Haemolytic assays andisolation of major proteins/I. Moreno-Indias, Dodds A.W., Arguello A., et al.//BMCVeterinary Research. – 2012. – V. 91. – N 8. – P. 1-9.116113. Nürnberger, W.
Preventive long-term intravenous immunoglobulin infusion inchildren with acute lymphatic leukemia. I. Anticomplementary activity of gammaglobulin preparations is a function of the preparation and IgG concentration prior toinfusions/W.Nürnberger,R.Willers,D.Körholz,etal.//MonatsschriftKinderheilkunde. – 1988. –V. 136. – N 3. – P. 116-120.114.
Ong, G.L. Rabbit complement lysis tumor cells without massive C3 deposition/G.L. Ong, P.B. Shah, M.J. Mattes//Immunol. Invest. – 1996. – V. 25. – N 3. – P. 215229.115. Radosevich, M. Intravenous immunoglobulin G: trends in production methods,quality control and quality assurance/M. Radosevich, T. Burnouf//Vox Sang. – 2010.– V. 98. – P. 12-28.116.
Ramasamy, I. Measurement of anticomplementary activity in therapeuticintravenous immunoglobulin preparations/I. Ramasamy, E. Tran, A. Farrugia//Biologicals: journal of the International Association of Biological Standardization. –1997. – V. 25. – N 1. – P. 87-92.117. Rieben, R. Immunoglobulin M – enriched human intravenous immunoglobulinprevents complement activation in vitro and in vivo in a rat model of acuteinflammation/R. Rieben, A. Roos, Y.
Muizert, et al.//Blood. – 1999. – V. 93. – N 3. –P. 942-951.118. Romer, J. Characterization of various immunoglobulin preparation for intravenousapplication. II. Complement activation and binding to Staphylococus Protein A/J. Romer, P. Spath, F. Skvaril//Vox Sang. – 1982. – V. 42. – P. 74-80.119. Rommel, F.A. Hemolytic complement in nonhuman primates/F.A. Rommel,D.W. Bendure, S.S. Kalter//Lab.
Anim. Sci. – 1980. – V. 30. – N 6. – P. 1026-1029.120. Sandberg, E. Collaborative study for establishment of human immunoglobulinbiological reference preparation (BRP)/E. Sandberg//Pharmeuropa Special Issue Bio.– 1996(1). – P. 49-69.121. Sandberg, E. Collaborative study for establishment of human immunoglobulinEuropean pharmacopoeia biological reference preparation batch 2/E.
Sandberg,117A. Daas, M.E. Esposito-Farese//Pharmeuropa Special Issue Bio. – 2001(1). – P. 2742.122. Sandberg, E. Collaborative study to establish human immunoglobulin BRP batch 3and human immunoglobulin (molecular size) BRP Batch 1/E.
Sandberg, M.-E. BehrGross, A. Daas//Pharmeuropa Bio. – 2006(1). – P. 37-48.123. Sandberg, E. Calibration of the human immunoglobulin BRPs for ACA andmolecular size (batch 1) and for Fc function and molecular size (batchs 1&2)/E. Sandberg, A. Costanzo, A. Daas, K.-H. Buchheit//Pharmeuropa Bio&SN. – 2012.– P. 1-15.124. Shirley, I. Anticomplementary activity of human immunoglobulin G/I. Shirley,Miekka, I.
Gozze//Vox Sang. – 1975. – V. 29. – N 2. – P. 101-123.125. Soler-Rodriguez, A.M. A new hemolytic assay for bovine serum complement andits application during experimental bovine anaplasmosis/A.M. Soler-Rodriguez,E. Romano, Y. Aranguren, et al.//Vet. Immunol. Immunopathol. – 1990. – V. 24. –N 4. – P.
347-360.126. Soltis, R.D. The effect of heat inactivation of serum on aggregation ofimmunoglobulin’s/R.D. Soltis, D. Hasz, M.J. Morris, et al.//Immunology. – 1979. –V. 36. – N 1. – P. 37-45.127. Stefanski, V. A new quantitative assay for the determination of complementactivity/V. Stefanski, H.G. Ruppel//Immunol. Lett. – 1991. – V.
30. – N 1. – P. 1-5.128. Stephan, W. Undegraded human immunoglobulin for intravenous use/W. Stephan//Vox Sang. – 1975. – V. 28. – N 6. – P. 422-437.129. Stephan, W. Beta-propiolactone as a sterilizing agent in the manufacture ofintravenousimmunoglobulinpreparations/W.Stephan,H.Dichtelmüller//Arzneimittel-Forschung. – 1983. – V. 33.
– N 9. – P. 1230-1231.130. Tanaka, K. A chromatographic method for the production of a humanimmunoglobulin G solution for intravenous use/K. Tanaka, E. Sawatani,E.M. Shigueoka, et al.//Brazilian Journal of Medical and Biological Research. –1998. – V. 31. – N 11. – P. 1375-1381.118131. Tanaka, S. Assay of classical and alternative pathway activities of murinecomplement using antibody-sensitized rabbit erythrocytes/S. Tanaka, T. Suzuki,K.
Nishoka//J. Immunol. Methods. – 1986. – V. 86. – N 2. – P. 161-170.132. Tao, M.H. Structural features of human immunoglobulin G that determine isotypespecific differences in complement activation/M.H. Tao, R.I. Smith, S.L. Morrison//J.Exp. Med. – 1996. – V. 183. – P. 2343-2348.133. Tsugikazu, T. A New Intact Immunoglobulin for Intravenous Use Stabilized byChemically Modified Gelatin Derivatives/T. Tsugikazu, I. Kazuyo, S. Tohru//VoxSang. – 1986. – N 51. – P.81-86.134. Uemura, Y.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
